Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Modern Rheumatology|July 10, 2010
Assessment of the validity of the 28-joint disease activity score using erythrocyte sedimentation rate (DAS28-ESR) as a disease activity index of rheumatoid arthritis in the efficacy evaluation of 24-week treatment with tocilizumab: subanalysis of the SATORI studyNorihiro Nishimoto, Nobuhiro Takagi
Modern Rheumatology|March 12, 2010
Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensionsNorihiro Nishimoto, Kyoko Ito, Nobuhiro Takagi
Langmuir : the ACS Journal of Surfaces and Colloids|February 13, 2013
Chemical propulsion using ionic liquidsShigeki Tsuchitani, Nobuhiro Takagi, Kunitomo Kikuchi, et al.
Shokuhin Eiseigaku Zasshi. Journal of the Food Hygienic Society of Japan|March 1, 2019
[Determination of Flufenacet and Its Metabolites in Agricultural Products by LC-MS/MS]Misako Imai, Nobuhiro Takagi, Mayuko Yoshizaki, et al.
Cell Reports|February 10, 2023
Decoding cellular deformation from pseudo-simultaneously observed Rho GTPase activitiesKatsuyuki Kunida, Nobuhiro Takagi, Kazuhiro Aoki, et al.
Blood|September 12, 2008
Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman diseaseNorihiro Nishimoto, Kimio Terao, Toru Mima, et al.
European Journal of Pharmacology|February 1, 2002
Polyglutamation of a novel antifolate, MX-68, is not necessary for its anti-arthritic effectKazumi Urakawa, Masahiko Mihara, Nobuhiro Takagi, et al.
Modern Rheumatology|September 8, 2017
Prodromal signs and symptoms of serious infections with tocilizumab treatment for rheumatoid arthritis: Text mining of the Japanese postmarketing adverse event-reporting databaseTatsuya Atsumi, Yoshiaki Ando, Shinichi Matsuda, et al.
Modern Rheumatology|July 15, 2016
Effectiveness and safety of tocilizumab in achieving clinical and functional remission, and sustaining efficacy in biologics-naive patients with rheumatoid arthritis: The FIRST Bio studyNaoki Ishiguro, Tatsuya Atsumi, Masayoshi Harigai, et al.
The Journal of Rheumatology|July 15, 2003
Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical studyNorihiro Nishimoto, Kazuyuki Yoshizaki, Keiji Maeda, et al.
Pageof 2